BRAF mutations in non-small cell lung cancer: has finally Janus opened the door? Review

Caparica, Rafael, de Castro, Gilberto, Gil-Bazo, Ignacio et al. (2016). BRAF mutations in non-small cell lung cancer: has finally Janus opened the door? . Critical Reviews in Oncology/Hematology, 101 32-39. 10.1016/j.critrevonc.2016.02.012

Open Access International Collaboration

cited authors

  • Caparica, Rafael; de Castro, Gilberto; Gil-Bazo, Ignacio; Caglevic, Christian; Calogero, Raffaele; Giallombardo, Marco; Santos, Edgardo S; Raez, Luis E; Rolfo, Christian

sustainable development goals

authors

publication date

  • May 1, 2016

published in

keywords

  • 1ST-LINE TREATMENT
  • ACTIVATION
  • B-Raf
  • B-Raf inhibitors
  • CHEMOTHERAPY
  • CLINICAL CHARACTERISTICS
  • Drug
  • Hematology
  • IMPROVED SURVIVAL
  • Life Sciences & Biomedicine
  • MEK INHIBITION
  • Mutation
  • NSCLC
  • Oncology
  • PROTEIN-KINASE PATHWAY
  • RAF INHIBITOR
  • RESISTANCE
  • Science & Technology
  • VEMURAFENIB

Digital Object Identifier (DOI)

start page

  • 32

end page

  • 39

volume

  • 101